Treatment Sequencing and Unmet Needs in aRCC

2024 ASCO® Annual Meeting Insights Hub
M

ASCO® 2024 Insights: "Systemic Treatments in Favorable and Very Favorable Risk mRCC - Real-World Evidence From the IMDC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Martin Zarba
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Martin Zarba
242 views
June 7, 2024
0 Comments
Login to view comments. Click here to Login
09:54

ASCO® 2024 Insights: "1L Systemic Therapy Following Adjuvant IO in R…

2024 ASCO® Annual Meeting Insights Hub

T. El Zarif

229 views
23:31

ASCO® 2024 Insights: "Harnessing the Immune System in RCC - Current …

2024 ASCO® Annual Meeting Insights Hub

D. Braun

196 views
17:33

1L Treatment Approaches in aRCC: Current Data, Treatment Selection, …

Benjamin Garmezy

251 views
11:30

HRQoL Data in aRCC: The Importance of Assessment and Impact on Clini…

Northwestern Medicine Oncology and Hematology

D. Cella

111 views
04:50

ASCO® GU 2024 Insights: "Nivo + Cabozantinib vs. Sunitinib for Previ…

Insights from 2024 ASCO® GU Annual Meeting

M. Bourlon

252 views
08:22

Role of C-met, AXL, and VEGFR3 in Clear Cell Renal Cancer

Pablo Maroto

150 views
22:03

RCC Highlights From ASCO® GU 2024

Dana-Farber Cancer Institute

W. Xu, T. Choueiri

331 views